Evaluation of synbiotic combinations of commercial probiotic strains with different prebiotics in in vitro and ex vivo human gut microcosm model

被引:0
|
作者
Raval, Shivani D. [1 ,2 ]
Archana, G. [1 ,2 ]
机构
[1] Maharaja Sayajirao Univ Baroda, Fac Sci, Dept Microbiol, Vadodara 390002, Gujarat, India
[2] Maharaja Sayajirao Univ Baroda, Fac Sci, Biotechnol Ctr, Vadodara 390002, Gujarat, India
关键词
Probiotic; Prebiotic; Synbiotic; Short chain fatty acids; Ex-vivo microcosm gut model; Bifidobacterium abundance; RIBOSOMAL-RNA-GENE; RESISTANT STARCH; HEALTHY-ADULTS; BIFIDOBACTERIA; MICROBIOTA; ACID; MODULATION; BUTYRATE; BACTERIA; METABOLISM;
D O I
10.1007/s00203-024-04030-3
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Exploring probiotics for their crosstalk with the host microbiome through the fermentation of non-digestible dietary fibers (prebiotics) for their potential metabolic end-products, particularly short-chain fatty acids (SCFAs), is important for understanding the endogenous host-gut microbe interaction. This study was aimed at a systematic comparison of commercially available probiotics to understand their synergistic role with specific prebiotics in SCFAs production both in vitro and in the ex vivo gut microcosm model. Probiotic strains isolated from pharmacy products including Lactobacillus sporogenes (strain not labeled), Lactobacillus rhamnosus GG (ATCC53103), Streptococcus faecalis (T-110 JPC), Bacillus mesentericus (TO-AJPC), Bacillus clausii (SIN) and Saccharomyces boulardii (CNCM I-745) were assessed for their probiotic traits including survival, antibiotic susceptibility, and antibacterial activity against pathogenic strains. Our results showed that the microorganisms under study had strain-specific abilities to persist in human gastrointestinal conditions and varied anti-infective efficacy and antibiotic susceptibility. The probiotic strains displayed variation in the utilization of six different prebiotic substrates for their growth under aerobic and anaerobic conditions. Their prebiotic scores (PS) revealed which were the most suitable prebiotic carbohydrates for the growth of each strain and suggested xylooligosaccharide (XOS) was the poorest utilized among all. HPLC analysis revealed a versatile pattern of SCFAs produced as end-products of prebiotic fermentation by the strains which was influenced by growth conditions. Selected synbiotic (prebiotic and probiotic) combinations showing high PS and high total SCFAs production were tested in an ex vivo human gut microcosm model. Interestingly, significantly higher butyrate and propionate production was found only when synbiotics were applied as against when individual probiotic or prebiotics were applied alone. qRT-PCR analysis with specific primers showed that there was a significant increase in the abundance of lactobacilli and bifidobacteria with synbiotic blends compared to pre-, or probiotics alone. In conclusion, this work presents findings to suggest prebiotic combinations with different well-established probiotic strains that may be useful for developing effective synbiotic blends.
引用
收藏
页数:17
相关论文
共 9 条
  • [1] Evaluation of the Prebiotic Potential of a Commercial Synbiotic Food Ingredient on Gut Microbiota in an Ex Vivo Model of the Human Colon
    Mottawea, Walid
    Sultan, Salma
    Landau, Kara
    Bordenave, Nicolas
    Hammami, Riadh
    NUTRIENTS, 2020, 12 (09) : 1 - 15
  • [2] Ex Vivo Murine Gut Model for Screening of Antibacterial Properties of Probiotic Strains
    Naughton, Violetta
    Naughton, Patrick
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2018, 52 : S100 - S100
  • [3] In vitro evaluation of physiological probiotic properties of different lactic acid bacteria strains of dairy and human origin
    Monteagudo-Mera, Andrea
    Rodriguez-Aparicio, Leandro
    Rua, Javier
    Martinez-Blanco, Honorina
    Navasa, Nicolas
    Rosario Garcia-Armesto, Maria
    Angel Ferrero, Miguel
    JOURNAL OF FUNCTIONAL FOODS, 2012, 4 (02) : 531 - 541
  • [4] Probiotic strains isolated from natural products alleviate gut inflammation in a human epithelial HT-29 in vitro model
    Park, Bo Ram
    Cheon, Se Jin
    Kim, Sae Hun
    PHYSIOLOGY, 2023, 38
  • [5] Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model
    Baines, Simon D.
    Noel, Alan R.
    Huscroft, Grace S.
    Todhunter, Sharie L.
    O'Connor, Rachael
    Hobbs, Joanne K.
    Freeman, Jane
    Lovering, Andy M.
    Wilcox, Mark H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (07) : 1537 - 1546
  • [6] A dynamic and integrated in vitro/ex vivo gastrointestinal model for the evaluation of the probability and severity of infection in humans by Salmonella spp. vehiculated in different matrices
    Godinez-Oviedo, A.
    Cuellar-Nunez, M. L.
    Luzardo-Ocampo, I.
    Campos-Vega, R.
    Hernandez-Iturriaga, M.
    FOOD MICROBIOLOGY, 2021, 95
  • [7] Valorization of Brewer's spent grain to prebiotic oligosaccharide: Production, xylanase catalyzed hydrolysis, in-vitro evaluation with probiotic strains and in a batch human fecal fermentation model
    Sajib, Mursalin
    Falck, Peter
    Sardari, Roya R. R.
    Mathew, Sindhu
    Grey, Carl
    Karlsson, Eva Nordberg
    Adlercreutz, Patrick
    JOURNAL OF BIOTECHNOLOGY, 2018, 268 : 61 - 70
  • [8] Evaluation of Probiotic Efficacy of Bacillus subtilis RODK28110C3 Against Pathogenic Aeromonas hydrophila and Edwardsiella tarda Using In Vitro Studies and In Vivo Gnotobiotic Zebrafish Gut Model System
    Nayak, Ashwath
    Harshitha, Mave
    Dubey, Saurabh
    Munang'andu, Hetron Mweemba
    Chakraborty, Anirban
    Karunasagar, Indrani
    Maiti, Biswajit
    PROBIOTICS AND ANTIMICROBIAL PROTEINS, 2023, 16 (5) : 1623 - 1637
  • [9] Sirolimus restrains nuclear processes of the restenosis-process in different human in-vitro/ex-vivo model:: Classification of the results with the SI/MPL-Ratio, image of the SI/DES-Ratio
    Voisard, R
    Zellmann, S
    Müller, E
    Fahlisch, F
    von Müller, L
    Baur, R
    Braum, J
    Gschwend, J
    Kountides, M
    Hombach, V
    MEDIZINISCHE KLINIK, 2006, 101 (04) : A55 - A55